Literature DB >> 16188325

(How) do aluminium adjuvants work?

James M Brewer1.   

Abstract

The aluminium compounds, originally identified as adjuvants over 70 years ago, remain unique in their widespread application to human vaccines. Given this history, it is surprising that the physicochemical interactions between aluminium compounds and antigens are relatively poorly understood. This has clearly been a contributing factor to vaccine failures, for example, through inappropriate selection of aluminium species or buffers. Similarly, the mechanism(s) of action of aluminium adjuvants are relatively unstudied, although it appears that these agents fail to fit within the current principles underlying activation of the immune response. This review aims to examine recent developments in our understanding of the physicochemical and biological aspects of research into aluminium adjuvants.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16188325     DOI: 10.1016/j.imlet.2005.08.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  56 in total

1.  A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.

Authors:  Waranyoo Phoolcharoen; John M Dye; Jacquelyn Kilbourne; Khanrat Piensook; William D Pratt; Charles J Arntzen; Qiang Chen; Hugh S Mason; Melissa M Herbst-Kralovetz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  Vaccines targeting drugs of abuse: is the glass half-empty or half-full?

Authors:  Kim D Janda; Jennifer B Treweek
Journal:  Nat Rev Immunol       Date:  2011-12-16       Impact factor: 53.106

Review 3.  Vaccines: all things considered.

Authors:  Ken S Rosenthal; Daniel H Zimmerman
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.

Authors:  C Venier; M D Guthmann; L E Fernández; L Fainboim
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

5.  Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.

Authors:  Sabena Uddowla; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-10-02       Impact factor: 3.641

Review 6.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

7.  IL-4 promotes stromal cell expansion and is critical for development of a type-2, but not a type 1 immune response.

Authors:  Diana Cortes-Selva; Andrew Ready; Lisa Gibbs; Bartek Rajwa; Keke C Fairfax
Journal:  Eur J Immunol       Date:  2019-01-03       Impact factor: 5.532

Review 8.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

Review 9.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

10.  The inflammasome and alum-mediated adjuvanticity.

Authors:  Suk-Jo Kang; Richard M Locksley
Journal:  F1000 Biol Rep       Date:  2009-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.